 This study is a multicenter, open-label trial that aimed to evaluate the safety and efficacy of CT-guided percutaneous irreversible electroporationIREin the treatment of patients with locally advanced tumors. Investigators will screen eligible patients and examine them by imaging tests as well as serological examination before and after the IRE procedures to assess the result with the size,blood supply,metabolism of tumors,the change of blood test and treatment-related complications. Big bore multislice spiral CT with thickness 5 cm, 120kilovolt,and 250milliampere,ECG-gated device and anesthesia monitoring equipment were selected during these procedures. Imaging performed by contrast enhanced CT scan and serological follow-up was at postoperative day 3 and 1,3,6,12months. The primary endpoint is the effective rate of IRE,and the secondary endpoint is 1-year survival rate and the frequency of adverse events. The response of irreversible electroporation ablation will be assessed according to the different evaluation criterions based on Response Evaluation Criteria in Solid Tumors. 